Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. Liu JF, Xiong N, Campos SM, Wright AA, et al. J Clin Oncol 2021;39:1531-1539.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu JF, Xiong N, Campos SM, Wright AA, et al. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol 2021;39:1531-1539.
PMID: 33705205